Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28695553 | 0.96 | KDM4E (0.50) | KDM4EALDH1A1HPGDNPSR1SLC6A2 | |
| SCHEMBL9480503 | 0.88 | CFTR (0.45) | KDM4EALDH1A1HPGDNPSR1SLC6A2 | |
| SCHEMBL29438041 | 0.86 | KDM4E (0.61) | KDM4EALDH1A1HPGDNPSR1SLC6A2 | |
| SCHEMBL68218 | 0.86 | KDM4E (0.61) | KDM4EALDH1A1HPGDNPSR1SLC6A2 | |
| SCHEMBL28680568 | 0.84 | MAPT (0.53) | KDM4EALDH1A1HPGDNPSR1SLC6A2 | |
| SCHEMBL28672585 | 0.84 | MAPT (0.57) | KDM4EALDH1A1HPGDNPSR1SLC6A2 | |
| SCHEMBL8383099 | 0.83 | PTPN11 (0.51) | KDM4EALDH1A1HPGDLMNAHSD17B10 | |
| SCHEMBL14666358 | 0.82 | CFTR (0.53) | KDM4EALDH1A1HPGDTSHRLMNA | |
| SCHEMBL9643407 | 0.81 | KDM4E (0.56) | KDM4EALDH1A1HPGDNPSR1SLC6A2 | |
| SCHEMBL2512793 | 0.79 | KDM4E (0.62) | KDM4EALDH1A1HPGDNPSR1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116693465-B | Amino compound and application thereof | 浙江八亿时空先进材料有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-116693465-A | Amino compound and application thereof | 浙江八亿时空先进材料有限公司 | 2023-09-05 | — | — | CN | disclosed |
| CN-113943287-B | Polycyclic aromatic compound and application thereof in electroluminescent device | 清华大学 | 2023-02-03 | — | — | CN | disclosed |
| CN-113943287-A | Polycyclic aromatic compound and application thereof in electroluminescent device | 清华大学 | 2022-01-18 | — | — | CN | disclosed |
| CN-113943290-A | Polycyclic aromatic compound and application thereof in electroluminescent device | 清华大学 | 2022-01-18 | — | — | CN | disclosed |
| EP-1363993-A4 | METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF I$g(k)B KINASE (IKK) | BRISTOL MYERS SQUIBB CO (US) | 2008-11-12 | — | — | EP | disclosed |
| EP-1325009-B1 | AMINO-SUBSTITUTED TETRACYCLIC COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL MYERS SQUIBB CO (US) | 2006-03-08 | — | — | EP | disclosed |
| US-6960585-B2 | Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| US-6869956-B2 | Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-22 | — | — | US | disclosed |
| EP-1363993-A2 | METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF I$g(k)B KINASE (IKK) | Bristol-Myers Squibb Company (US) | 2003-11-26 | — | — | EP | disclosed |
| EP-1325009-A2 | AMINO-SUBSTITUTED TETRACYCLIC COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | Bristol-Myers Squibb Company (US) | 2003-07-09 | — | — | EP | disclosed |
| US-20030022898-A1 | Methods of treating inflammatory and immune diseases using inhibitors of IkappaB kinase (IKK) | BRISTOL-MYERS SQUIBB COMPANY | 2003-01-30 | — | — | US | disclosed |
| WO-2002060386-A2 | METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF IλB KINASE (IKK) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-08 | — | — | WO | disclosed |
| US-20020072523-A1 | Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2002-06-13 | — | — | US | disclosed |
| WO-2002028860-A2 | AMINO-SUBSTITUTED TETRACYCLIC COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072523-A1 | Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same | IL4, IL4I1, MSR1 | KDM4E 595/4885ALDH1A1 1556/4885HPGD 2777/4885 |
| US-20030022898-A1 | Methods of treating inflammatory and immune diseases using inhibitors of IkappaB kinase (IKK) | NFKBIA, IKBKG, IKBKB | KDM4E 327/4885ALDH1A1 2991/4885HPGD 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.